Skip to main content

Table 3 Summary of baseline and change data for lung function and validated questionnaires

From: Bronchiectasis Information and Education: a randomised, controlled feasibility trial

 

No.

Control group (n = 29)

No.

Intervention group (n = 31)

Baseline mean (SD)

Mean changea, baseline to 2 weeks (SD)

Mean change, baseline to 12 weeks (SD)

Baseline mean (SD)

Mean change, baseline to 2 weeks (SD)

Mean change, baseline to 12 weeks (SD)

EQ-5D-5Lb

 Index value

29

0.75 (0.24)

0.01 (0.17)

 -0.5 (0.19)

31

0.70 (0.23)

0.06 (0.13)

2.11 (11.7)

 VAS

29

68.6 (18.5)

−1.55 (13.0)

0.48 (16.2)

31

65.4 (18.0)

5.97 (12.0)

−3.0 (16.7)

SGRQc

 Symptoms

29

57.6 (23.4)

 

0.25 (15.0)

30

65.9 (21.3)

 

−7.89 (25.7)

 Activity

27

56.3 (23.5)

 

–4.85 (13.4)

31

56.1 (28.3)

 

−4.79 (14.8)

 Impacts

29

33.6 (21.5)

 

0.02 (11.3)

31

32.9 (17.2)

 

−3.06 (13.0)

 Total

27

46.1 (19.9)

 

−1.53 (8.3)

30

44.9 (19.1)

 

−2.62 (9.46)

QOL-Bd

 Physical

29

48.1 (32.3)

2.30 (17.8)

-3.85 (16.7)

30

51.6 (35.1)

3.11 (16.2)

-4.94 (25.2)

 Role

29

63.5 (29.3)

0.23 (13.6)

1.32 (17.6)

30

64.9 (25.8)

5.33 (18.7)

2.22 (17.8)

 Vitality

29

44.1 (24.0)

–1.53 (18.5)

0.38 (16.9)

30

43.7 (22.4)

4.44 (18.4)

-0.74 (21.0)

 Emotion

29

84.0 (17)

1.05 (14.9)

-2.1 (13.0)

30

85.0 (18.6)

4.44 (15.3)

2.22 (10.2)

QOL-B

        

 Social

29

59.7 (31.2)

-0.077 (22.1)

2.97 (14.7)

30

58.1 (22.8)

5.37 (17.2)

3.14 (19.0)

 Treatment burdene

21

71.2 (22.7)

–1.06 (16.8)

0.53 (14.7)

22

71.7 (21.6)

2.02 (14.8)

1.01 (14.1)

 Health

29

45.0 (25.3)

1.25 (18.2)

-0.10 (13.0)

30

44.0 (24.3)

7.04 (15.8)

3.06 (18.4)

 Respiration

28

60.6 (23.7)

3.97 (17.3)

3.6 (16.3)

30

54.3 (22.8)

9.7 (14.6)

6.3 (16.8)

HADSf

 A

29

5.69 (3.87)

–0.14 (2.86)

–0.31 (3.11)

31

5.87 (4.01)

−1.32 (2.4)

0.44 (6.6)

 D

29

4.52 (3.61)

0.00 (2.38)

0.14 (1.76)

31

3.81 (2.33)

−0.10 (1.7)

2.12 (13.2)

FISg

 Cognitive

29

8.52 (9.44)

 

2.07 (7.2)

31

7.55 (5.84)

 

1.26 (5.7)

 Physical

29

15.52 (12.3)

 

−1.69 (5.6)

31

12.9 (8.18)

 

0.39 (6.9)

 Social

29

21.79 (21.95)

 

−0.59 (8.8)

31

15.7 (13.4)

 

2.72 (12.9)

 Total

29

45.8 (42.5)

 

−0.21 (18.3)

31

36.2 (26.0)

 

2.70 (19.7)

FEV1 (% predicted)

28

72.6 (26.7)

 

3.78 (8.61)

30

63.7 (23.8)

 

−0.78 (10.1)

FEV1 (L)

28

1.82 (0.73)

 

0.08 (0.23)

30

1.64 (0.75)

 

0.23 (1.15)

  1. Abbreviations: EQ-5D-5L 5-level EuroQol 5-dimension quality of life scale, FEV1 forced expiratory volume in 1 s, FIS Fatigue Impact Scale, HADS Hospital Anxiety and Depression Scale, QOL-B Quality of Life–Bronchiectasis, SGRQ St George’s Respiratory Questionnaire, VAS visual analogue scale
  2. aA negative change indicates a numerical fall, on average, from baseline to 12 weeks
  3. bEuroQol-5D-5L: self-reported health status (VAS range, 0–100%)
  4. cSt George’s Respiratory Questionnaire: scores are a percentage of overall impairment; 100 represents worst possible health status, and 0 indicates best possible health status
  5. dQuality of Life – Bronchiectasis: scored 0–100, higher score = better quality of life
  6. eTreatment burden is not scored if participant is receiving no treatment, hence apparent lower n value
  7. fHospital Anxiety and Depression Scale: anxiety 0–21, depression 0–21; scores 11+ are significant
  8. gFatigue Impact Scale: cognitive, 0–40; physical, 0–40; social, 0–80; total, 0–160. Higher score = bigger impact of fatigue
Back to article page

Trials

ISSN: 1745-6215